Kardi Ai raises €5.3M Series A to take AI cardiac monitoring from Czech hospitals into Germany and beyond

Kardi Ai (Olomouc, Czech Republic) has raised €5.3 million (CZK 130 million) in a Series A led by Callisto Health, a German healthtech venture fund, with Seed Starter (a joint fund of Česká spořitelna and Slovenská sporiteľňa), BrightCap Ventures, Purple Ventures, DEPO Ventures, and Garage Angels participating. The company makes an AI-powered cardiac monitoring platform combining a wearable ECG chest strap, a mobile application, and cloud-based arrhythmia analysis. The platform is currently deployed in more than 70 Czech hospitals and 20-plus Slovak physician practices, with more than 6,000 users on the system.

The round follows a €1.1 million seed in April 2025 and is described by the company as the largest round raised by a Czech medtech startup — a claim that cannot be independently verified from available sources. The €5.3M funds geographic expansion into Germany, UAE, Singapore, and India, alongside a second product track: predictive arrhythmia risk models that aim to flag elevated cardiac risk before an event occurs.

Why wearable changes the equation

Hospital ECG monitoring has a structural limitation: it captures the heart only while the patient is physically present. Holter monitors extend coverage to 24 or 48 hours, but intermittent arrhythmias may not manifest in that window, and reviewing every recording requires specialist time. Kardi Ai's premise is that extending monitoring into weeks or months using a consumer-grade chest strap — worn during activity and sleep — and routing the signal through AI rather than specialist review changes the economics of cardiac screening materially.

The platform holds MDR Class IIa certification for active diagnostic devices in the EU and UAE medical device registration, with Singapore in progress. The company reports that its AI has flagged potential arrhythmias in approximately 25% of users screened, including more than 500 findings categorised as clinically critical. Those figures originate from the company; the depth of the hospital network is the more independently verifiable data point.

Callisto Health and the German expansion

Callisto Health, which led the round, invests at the intersection of AI and clinical healthcare in Germany and the DACH region. Its lead is a direct alignment signal: Germany is Kardi Ai's primary expansion target. Adoption of a diagnostic medical device in German clinical settings requires navigating hospital procurement processes, physician reimbursement pathways, and potentially a Health Technology Assessment — timelines that typically extend 12 to 18 months from initial hospital contact.

Seed Starter, the Czech-Slovak savings-bank co-investment vehicle, BrightCap Ventures (Sofia), and Purple Ventures anchor the round's Central and Eastern European coverage. The UAE and Singapore expansions are sequenced after Germany; both markets have either cleared regulatory registration or are near to it. India — which the CEO's quote gestures at with the two-billion-person figure — is a longer-term market development play at this funding level.